OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Cancer is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Revumenib: a new era in acute leukemia treatment	355
Subscription & copyright page	230
FBXW10: a male-biased E3 ligase in liver cancer	229
Spliced to kill: RNA mis-splicing derived cancer neoantigens	206
Platelets: tailoring metastasis treatment	189
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	181
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy	179
Engineering growth factor ligands and receptors for therapeutic innovation	179
Tumor-resident microbes: the new kids on the microenvironment block	171
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	161
Navigating life as an early career researcher	159
Subscription and copyright page	157
Advisory Board and Contents	155
Subscription & copyright page	143
Onco-condensates: formation, multi-component organization, and biological functions	141
Accessing the vasculature in cancer: revising an old hallmark	140
Leveraging circulating microbial DNA for early cancer detection	132
Engine shutdown: migrastatic strategies and prevention of metastases	131
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	124
Radiotherapy and immunotherapy: open questions and future strategies	119
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	97
Subscription & copyright page	93
GOT2 consider the tumor microenvironment	92
Recent developments in myeloid immune modulation in cancer therapy	89
Neural hijacking in cancer metabolism: from nutrients to organelles	87

The evolving landscape of brain metastasis: volume II	87
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	83
Oncogenic competence: balancing mutations, cellular state, and microenvironment	83
Chromatin as an old and new anticancer target	82
Benefits and opportunities of the transgenic Oncopig cancer model	81
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	79
Cell death, therapeutics, and the immune response in cancer	79
Diet, nutrient supply, and tumor immune responses	75
Crosstalk of T cells within the ovarian cancer microenvironment	71
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	70
Tumor immunology CRISPR screening: present, past, and future	70
Chromosomal instability and aneuploidy as causes of cancer drug resistance	69
Regulation of metastatic organotropism	67
Gut microbiota – a double-edged sword in cancer immunotherapy	66
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	63
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	61
Advisory Board and Contents	60
Subscription & copyright page	59
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	58
Cancer catecholamine conundrum	58
Advisory Board and Contents	57
Scaling data toward pan-cancer foundation models	57
Advisory Board and Contents	55
Subscription & copyright page	55
Organellar pH as an emerging vulnerability to exploit in cancer	54
Palmitate paves the way to lung metastasis	54
Inflammation: the incubator of the tumor microenvironment	53
Insights on ErbB glycosylation – contributions to precision oncology	53
Genetic immune escape in cancer: timing and implications for treatment	52
The emerging field of oncolytic virus-based cancer immunotherapy	51
Clinical and translational relevance of intratumor heterogeneity	49
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence	48
Prospects for understanding and exploiting the consequences of hyperactivation lethality	47
Subscription & copyright page	47
Emerging mechanisms of telomerase reactivation in cancer	47
Subscription and copyright page	46
B7-H3: a robust target for immunotherapy in prostate cancer	46
Advancing cancer precision surgery with the tumor coagulome	46
Updating cancer research with patient-focused networks	45
Advisory Board and Contents	45
Molecular and clinical insights into early-onset endometrial cancer	45
Advisory Board and Contents	45
Advisory Board and Contents	44
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer	44
Advisory Board and Contents	44
Circulating cell-free DNA-based multi-cancer early detection	43
Cuproptosis in cancer: from molecular mechanisms to therapeutic intervention	43
RHOA takes the RHOad less traveled to cancer	42
Redefining precision cancer prevention to promote health equity	42
Stress granules and hormetic adaptation of cancer	42

Advisory Board and Contents	41
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development	41
Advisory Board and Contents	41
Leveraging space innovations for cancer breakthroughs on Earth	40
Targeting TIM-3 to halt lung precancer progression	40
Advisory Board and Contents	40
Beyond safety: suicide systems in cell-based cancer therapies	40
CAR T cell persistence in cancer	40
The promise of TIL therapy for glioblastoma	40
Subscription & copyright page	39
Time-of-day dependency of adoptive cell therapies	39
RNA vaccines for cancer: revolutionizing immunization strategies	39
A macrophage-neutrophil program drives mammary carcinogenesis	39
Advisory Board and Contents	38
Dissecting liver tumor heterogeneity to improve health equity	37
Cross-dressing of dendritic cells strengthens antitumor immunity	37
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes	36
Branched chain amino acids and their aberrant metabolism in cancer	36
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations	36
Orchestrating tumor-immune epigenetics via SERT–H3Q5ser axis	36
Neoantigen-directed therapeutics in the clinic: where are we?	35
A tipping point in cancer epidemiology: embracing a life course exposomic framework	35
Immune response and inflammation in cancer health disparities	34
Functional heterogeneity of fibroblasts in primary tumors and metastases	33
Subscription & copyright page	32
Ferroptosis vulnerability in FLT3-mutant leukemia	32
Advisory Board and Contents	32
Advisory Board and Contents	31
Tumor-draining lymph nodes – friend or foe during immune checkpoint therapy?	30
Epigenetic basis and targeting of cancer metastasis	30
Advisory Board and Contents	30
ApCAFs: spatial niches and therapeutic insights across cancers	29
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	29
Engineered bacterial therapeutics for detecting and treating CRC	29
Subscription & copyright page	28
Space in cancer biology: its role and implications	28
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	28
Clonal evolution and hierarchy in myeloid malignancies	28
Dying to survive: harnessing inflammatory cell death for better immunotherapy	28
The development of therapy related myeloid neoplasms in childhood cancer survivors	27
Subscription & copyright page	27
Next-generation cancer vaccines and emerging immunotherapy combinations	27
Advisory Board and Contents	27
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	27
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	26
Addressing the genetic/nongenetic duality in cancer with systems biology	26
Mapping heterogeneity in the tumor microenvironment of renal cell carcinoma through single-cell omics	25
Immunomodulation by endothelial cells: prospects for cancer therapy	25
NETscape or NEThance: tailoring anti-cancer therapy	25
Lifileucel: the first cellular therapy approved for solid tumours	25
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	25
Subscription & copyright page	25
Genitourinary cancer neoadjuvant therapies: current and future approaches	25
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	25
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome	24
Persisting cancer cells are different from bacterial persisters	24
Successfully targeting the cancer system with metronomics for medulloblastoma	24
Future perspectives on engineered T cells for cancer	23
Embracing diversity: macrophage complexity in cancer	23
Tissue architecture in tumor initiation and progression	23
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	23
The extracellular matrix in cancer: from understanding to targeting	23
How cancer cells make and respond to interferon-I	22
Think zebras: challenges and opportunities for treating rare cancers	22
NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis	22
Emerging and extensive clonal evolution in the pancreas	22
Deciphering the roles of ABCB5 in normal and cancer cells	22